Vanguard Group Inc. Boosts Stock Position in Cencora, Inc. $COR

Vanguard Group Inc. lifted its position in Cencora, Inc. (NYSE:COR) by 4.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,395,547 shares of the company’s stock after buying an additional 916,506 shares during the period. Vanguard Group Inc. owned approximately 12.07% of Cencora worth $7,311,810,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the period. Mediolanum International Funds Ltd boosted its stake in Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after buying an additional 32,138 shares in the last quarter. Segment Wealth Management LLC acquired a new position in Cencora during the third quarter worth about $4,830,000. Finally, Advisors Asset Management Inc. raised its position in Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after acquiring an additional 4,973 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on COR shares. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Evercore decreased their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday. Bank of America reduced their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Finally, Robert W. Baird set a $415.00 target price on Cencora in a research report on Tuesday, January 13th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Cencora Trading Up 2.7%

NYSE:COR opened at $360.59 on Tuesday. The stock has a market cap of $70.15 billion, a PE ratio of 43.34, a price-to-earnings-growth ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock’s 50-day moving average is $347.97 and its two-hundred day moving average is $329.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.73 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 15,220 shares of company stock worth $5,282,867. Insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.